RNAC Selecta Biosciences Inc

$RNAC if phase 3 meets the primary end point with similar efficient of phase 2, there is a potential for ABIVAX 2.0. Recent data is also nice, even though n=5. That means there might be a constant revenue as well with once in every 1-2 years of dosing. Only problem is dosing takes 6 weeks, it’s too long.